AMENDMENT TO
RULES COMMITTEE PRINT 116–41
OFFERED BY MR. CÁRDENAS OF CALIFORNIA

Add at the end of title VIII the following new section (and amend the table of contents accordingly):

SECTION 812. DEMONSTRATION PROJECT TO INCREASE ACCESS TO BIOSIMILAR BIOLOGICAL PRODUCTS UNDER THE MEDICARE PROGRAM.

(a) Establishment.—Beginning not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services shall establish and implement a 3-year nationwide demonstration project under part B of title XVIII of the Social Security Act to evaluate the benefits of providing a shared savings payment for biosimilar biological products furnished under such part.

(b) Participation.—

(1) In general.—Participation under the demonstration project shall be voluntary, and a participating provider may terminate participation at any time and the Secretary may terminate the participation of such a provider at any time.
(2) Application and Selection.—To participate under the demonstration project, an eligible provider shall submit to the Secretary an application in such form and manner and containing such information as specified by the Secretary. Each eligible provider who submits such an application shall be selected by the Secretary for participation under the demonstration project.

(c) Coverage.—Except as otherwise provided in this section, payment may be made under the demonstration project for a biosimilar biological product only if such product is covered under part B of title XVIII of the Social Security Act and such payment shall be made in the same manner as payment is provided for such a product under such part.

(d) Additional Payment.—Under the demonstration project, in addition to the payment that would otherwise be made under part B of title XVIII of the Social Security Act for a biosimilar biological product furnished or dispensed by a participating provider to a Medicare beneficiary, there shall be made an additional payment, in an amount determined by the Secretary, that reflects a portion of any difference between the that may result from furnishing the biosimilar biological product, as compared to the reference biological product.
(c) Waiver Authority.—The Secretary may waive such requirements of title XVIII of the Social Security Act as may be necessary to carry out the demonstration project.

(f) Reports.—

(1) Interim Evaluation and Report.—Not later than 3 years after the date of enactment of this Act, the Secretary shall submit to Congress a report that contains an analysis of the appropriateness of expanding or extending the demonstration project and, to the extent such analysis determines such an expansion or extension appropriate, recommendations for such expansion or extension, respectively.

(2) Final Evaluation and Report.—Not later than one year after the date of completion of the demonstration project, the Secretary shall submit to Congress a report that contains a final analysis of the project and recommendations described in paragraph (1).

(g) Definitions.—In this section:

(1) Demonstration Project.—The term “demonstration project” means the demonstration project conducted under this Act.
(2) BIOSIMILAR BIOLOGICAL PRODUCT.—The
term “biosimilar biological product” means a biologi-
cal product approved under an abbreviated applica-
tion for a license of a biological product that relies
in part on data or information in an application for
another biological product licensed under section 351
of the Public Health Service Act (42 U.S.C. 262) .

(3) ELIGIBLE PROVIDER.—The term “eligible
provider” means a provider of services or supplier
that is eligible to receive payment under part B of
title XVIII of the Social Security Act for furnishing
or dispensing biosimilar biological products.

(4) MEDICARE BENEFICIARY.—The term
“Medicare beneficiary” means an individual who is
enrolled for benefits under part B of title XVIII of
the Social Security Act.

(5) PARTICIPATING PROVIDER.—The term
“participating provider” means an eligible provider
that has been selected for participation under the
project under subsection (b)(2) and with respect to
whom such participation has not been terminated.

(6) REFERENCE BIOLOGICAL PRODUCT.—The
term “reference biological product” means the bio-
logical product licensed under section 351 of the
Public Health Service Act (42 U.S.C. 262) that is
referred to in the application described in paragraph (2) of the biosimilar biological product.